August 2007- Volume 3, Issue 8

August 2007

In this Issue

Global News

Delaying the inevitable?

Delaying the inevitable?

A commonly expressed concern about building new antibiotics on the scaffolds of failing first-generation compounds is that the new drugs typically target the same molecular pathways as the originals and therefore microbes resistant to the old compound will rapidly become resistant to the new ones.

Decorating old drugs to combat resistance

Decorating old drugs to combat resistance

In a recent issue of the Journal of the American Chemical Society, researchers at the University of Wisconsin-Madison and Milwaukee’s Medical College of Wisconsin described their efforts to bring new life to old antibiotics that are quickly being made obsolete by multidrug-resistant microbes.

Amgen, Daiichi Sankyo reach deal on bone antibody

Amgen, Daiichi Sankyo reach deal on bone antibody

Amgen and Daiichi Sankyo Co. Ltd. have announced a collaboration and license agreement for the development and commercialization of denosumab in Japan.

Opening the coffers

Opening the coffers

Congress moves toward increasing funding for FDA’s drug efforts

Genomics & Proteomics

Jumping into the RNA fray

Jumping into the RNA fray

Deal with Silence Therapeutics gives AstraZeneca a good foot forward in siRNA research

Divining origins of diabetes

Divining origins of diabetes

Researchers identify new gene for type 1 diabetes

Informatics

Planning ahead

Planning ahead

New software technologies help Parexel team enhance clinical trial recruitment and execution

Staying on the alert

Staying on the alert

Sentrx adds Clintrace pharmacovigilance product to its lineup

Giving it away for free

Giving it away for free

NimbleGen to distribute DNASTAR software

Adapt or die

Adapt or die

Cytel and Tourtellotte bring more predictability to adaptive trials

Research & Development

Broad cancer collaboration

Broad cancer collaboration

Merck shells out $75 million upfront to co-develop Ariad’s mTOR inhibitor for multiple cancer indications

CHF cohorts

CHF cohorts

Biogen Idec, Cardiokine to co-develop a new drug for treating congestive heart failure

Merck pumps up pipeline

Merck pumps up pipeline

Will purchase NovaCardia for $350 million in stock

A new hope for pain

A new hope for pain

Tikvah, Apkarian strike licensing agreement for chronic pain treatments

Editor's Focus

Emptying the drawer of the editorial mind

Emptying the drawer of the editorial mind

Here are a few thoughts that rattled around in my mind as I walked the floor of this year’s Drug Discovery and Development of Innovative Therapeutics (DDT) show and conference in Boston recently

Automation & Instrumentation

Go with the flow

Go with the flow

Thar Instruments acquires Berger SFC from Mettler Toledo

Assay assistants

Assay assistants

Nanostream creates new division to create customized assays

Illumina is striking a vein

Illumina is striking a vein

Illumina to help consortium illuminate genetic causes of vascular disease

Turbocharging drug production

Turbocharging drug production

Xcellerex works to speed up protein and vaccine manufacturing
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022